Tretinoin for Hyperpigmentation: Evidence and Timelines

Tretinoin for hyperpigmentation may fade some post-inflammatory marks and diagnosed melasma. The likely effect depends on the cause, and irritation can worsen pigmentation. The studies used particular strengths and populations, so their results cannot predict an individual response. In the UK, tretinoin treatment starts with a prescriber, who should confirm the diagnosis and suitability.
Dark marks have different causes. This guide looks at evidence for tretinoin for hyperpigmentation, including post-inflammatory hyperpigmentation (PIH), melasma and sun spots, and explains when to seek medical advice. Some searches use “Retin A” for tretinoin. This article discusses study evidence; the UK product information cited here is for Treclin.
What tretinoin for hyperpigmentation can and cannot do
Studies have examined tretinoin for some kinds of dark marks. The clearest evidence discussed here concerns PIH, melasma and mottled pigmentation in photodamaged skin. It does not establish tretinoin as a treatment for every brown spot or a way to change natural skin colour.
The UK Treclin SmPC describes a prescription-only gel containing clindamycin and tretinoin for acne. The cited indication is acne. Tretinoin also appears in the prohibited-substances annex for cosmetic products. That rule applies to cosmetics; the Treclin entry covers a prescription medicine (eMC Treclin SmPC; Cosmetics Regulation, Annex II).
If acne leaves flat marks, those are different from indented or raised scars. Read more about how acne marks differ from indented scars.
PIH, melasma and sun spots are different
PIH follows skin inflammation or injury, melasma often appears as paired patches, and solar lentigines are flat marks on sun-exposed skin; appearance alone cannot confirm which one you have. These conditions have different causes and evidence, so a diagnosis matters before treatment is considered.
| Type | What it describes | Evidence and limits for tretinoin |
|---|---|---|
| Post-inflammatory hyperpigmentation (PIH) | Darker marks left after inflammation or injury, including acne or dermatitis. | A vehicle-controlled trial studied PIH in Black patients. It does not establish a result for every cause, site or formulation. (DermNet: PIH) |
| Melasma | Often paired, irregular brown patches. It can be difficult to treat and may return. | Small trials studied diagnosed melasma; they do not show that every patch is melasma or that one treatment suits everyone. (DermNet: melasma; PCDS guidance) |
| Solar lentigines, or sun spots | Flat pigmented spots commonly found on sun-exposed skin. | A trial of photodamaged facial skin reported improvement in mottled pigmentation. It did not test tretinoin as a treatment for every individual solar lentigo. (DermNet: solar lentigo) |
PIH can follow a breakout, but the acne itself may still need attention. Do not assume a new or isolated mark is an acne mark, particularly if it changes.
What the studies show, including skin of colour
Clinical trials report possible improvement for specific diagnoses, and also describe irritation. Their findings cannot predict an individual response to a different product or treatment plan. We reviewed the abstracts and retained each result’s population, treatment period and limitations.
Post-inflammatory pigmentation in Black patients
In a randomised, double-blind, vehicle-controlled study, 54 Black participants with inflammatory hyperpigmented lesions completed 40 weeks. Participants received daily 0.1% tretinoin cream or vehicle cream. Overall improvement was first noted after four weeks.
At the end, colour measurement showed a 40% change towards normal skin colour in treated lesions compared with 18% with vehicle. Retinoid dermatitis occurred in 12 of 24 tretinoin completers. The findings describe outcomes in the participants studied (Bulengo-Ransby et al., PMID 8479462).
That trial directly examined post-inflammatory marks in Black patients, which is useful evidence for skin of colour. It was still an older study of a particular concentration and cream. It cannot tell a reader whether a mark is PIH, whether another formulation will have the same effect, or whether irritation will occur.
Melasma trials
In a randomised vehicle-controlled trial, 38 women with melasma completed 40 weeks of once-daily 0.1% tretinoin or vehicle cream.
Significant improvement first occurred after 24 weeks. At the end, 13 of 19 tretinoin-treated participants were rated improved or much improved, compared with 1 of 19 on vehicle. Moderate redness and scaling occurred in 88% and 29%, respectively (Griffiths et al., PMID 8217756).
Another vehicle-controlled trial enrolled 30 Black patients with melasma, with 28 completing a 10-month study of daily 0.1% tretinoin or vehicle cream. At 40 weeks, the melasma severity score improved by 32% in the tretinoin group and 10% in the vehicle group. Mild retinoid dermatitis was reported in 67% of tretinoin-treated patients (Kimbrough-Green et al., PMID 8002642).
Photodamage and evidence reviews
Photodamaged skin is a separate evidence category. In a randomised, double-blind, multicentre study of 296 people with photodamaged facial skin, 0.05% emollient tretinoin cream was compared with vehicle for 24 weeks. The study reported greater improvement in mottled hyperpigmentation with tretinoin. It did not test isolated sun spots or prove that all pigmentation responds similarly (Olsen et al., PMID 1552056).
A Cochrane review of melasma treatments found that two studies using objective measures showed reduced severity with tretinoin, while describing the overall study quality as generally poor and available treatments as inadequate. Its findings support cautious discussion and offer no ranking or promise (Rajaratnam et al., PMID 20614435).
How long might fading take?
The time to change varied by diagnosis and study; there is no supported universal timeline for tretinoin fading. In the PIH trial, investigators first noted overall improvement after four weeks, with the measured outcome reported after the 40-week treatment period. In one melasma trial, significant improvement first appeared after 24 weeks. Those results came from studies of 0.1% cream and do not forecast the effect of another formulation (PMID 8479462; PMID 8217756).
The Primary Care Dermatology Society says some patients with melasma benefit from topical tretinoin, but treatment may need to continue beyond 24 weeks. It also notes that melasma can be difficult to treat and can recur (PCDS clinical guidance). A clinician can review whether the diagnosis or plan needs reconsidering if marks persist.
Irritation can worsen pigmentation
Yes, irritation can lead to more inflammation and may worsen PIH, including in skin of colour. A review of PIH treatments advises caution to prevent irritation and worsening marks (Davis and Callender, PMID 20725554). PCDS guidance also warns that irritation which does not settle may worsen pigmentation in skin of colour (PCDS).
The trial figures above show why tolerance matters: irritation was reported in each study, though rates differed by population and study design. Irritation does not show that treatment is working. Do not increase the amount or frequency yourself, or continue through a persistent reaction.
Speak to the prescriber, GP, pharmacist or dermatologist if you experience:
- persistent or painful burning, redness, peeling or swelling
- new or worsening dark marks after irritation
- a rash, marked discomfort or symptoms affecting your eyes
- uncertainty about whether a mark or reaction needs assessment
For more detail, see tretinoin side effects and when to seek help and guidance on tretinoin and sensitive skin.
Irritation rates varied across these small studies and cannot predict an individual’s response. Persistent irritation or worsening pigmentation needs advice from the prescriber.
Sun protection and daily skin care
Sun protection is part of managing melasma and is included in the Treclin product information, but it cannot guarantee that pigmentation will fade. PCDS advises year-round UV protection for melasma, including shade, a hat and sunscreen. Treclin's SmPC advises sunscreen of at least SPF 30 and protective clothing while using that product; this guidance applies to that product and does not set a tretinoin dose (PCDS; eMC Treclin SmPC).
Keep other skincare simple if your clinician advises treatment and your skin is irritated. A gentle cleanser and moisturiser may help keep your skin comfortable. Your diagnosis and treatment advice should come from a clinician. See general tretinoin routine guidance for broader routine context.
Combination treatment needs a prescriber
Whether tretinoin should be combined with another medicine depends on the diagnosis and requires a prescriber's decision. Evidence here does not establish that hydroquinone, azelaic acid or another ingredient will produce a faster or better result for you.
Some prescription melasma treatments combine hydroquinone and tretinoin with a corticosteroid. A steroid-containing combination has its own risks and needs medical supervision. Do not start, layer or alter prescription treatments based on another person's routine or an online before-and-after image.
For background, read our separate pages on tretinoin and hydroquinone and hydroquinone and melasma safety. These pages provide general information; speak with a prescriber before combining medicines.
When to speak to a GP or dermatologist
Ask a GP or dermatologist to assess a new, changing or uncertain mark. NHS advice says a mole that changes in size, shape or colour should be checked by a GP (NHS melanoma symptoms).
Before the appointment, it may help to note:
- when you first noticed the mark and whether it has changed
- whether acne, irritation or another skin problem came before it
- which prescribed or non-prescribed products you have used on the area
Arrange clinical advice if irritation persists, pigmentation is worsening, the diagnosis is unclear, or the marks continue despite the plan you were given. A pharmacist can advise on a medicine-related reaction, and a GP can assess a changing lesion or refer you when needed.
Safety: pregnancy and prescription use
Tretinoin for hyperpigmentation should not be used during pregnancy or when trying to conceive. NICE says topical retinoids are contraindicated during pregnancy and when planning pregnancy; BUMPS also says retinoid creams and gels should not be used in pregnancy (NICE NG198; BUMPS). Speak to your prescriber if pregnancy is possible or planned.
The eMC entry cited here is for Treclin, a prescription-only clindamycin and tretinoin gel for acne. The Cosmetic Products Regulation lists tretinoin among substances prohibited in cosmetics, a rule that applies to cosmetics rather than medicines (eMC; legislation.gov.uk). Do not self-prescribe or use a product outside a prescriber’s instructions.
Frequently asked questions
Can tretinoin remove hyperpigmentation?
Tretinoin may fade some diagnosed forms of hyperpigmentation, especially post-inflammatory marks, but the evidence does not show that it removes every kind of dark patch. Small trials studied particular groups, formulations and diagnoses. Irritation can also worsen post-inflammatory pigmentation, so a prescriber should confirm the cause and decide whether tretinoin is appropriate.
How long does tretinoin take to fade dark spots?
There is no reliable timeline for every person or mark. In a randomised trial of post-inflammatory pigmentation in Black patients, improvement was first noted after four weeks, while a separate melasma trial found significant improvement after 24 weeks. Both used 0.1% tretinoin and continued for 40 weeks, so those timings should not be treated as a personal forecast.
Can tretinoin make pigmentation worse?
Yes. Tretinoin can cause irritation, and inflammation may leave or deepen post-inflammatory marks, including in skin of colour. Stop using it and contact the prescriber if irritation is persistent, painful or worsening, or if new dark marks appear.
Does tretinoin help with melasma?
Some clinical trials found improvement in diagnosed melasma, but they studied small groups and a specific 0.1% cream over a long treatment period. Melasma can be difficult to treat and may recur. A GP or dermatologist can confirm the diagnosis and discuss options; these studies do not show that tretinoin alone is suitable for everyone.
Is tretinoin or hydroquinone better for hyperpigmentation?
The evidence cited here does not establish one as better for an individual. The right option depends on the diagnosis, medical history and likely irritation. Hydroquinone and tretinoin, including steroid-containing triple-combination creams, need prescriber oversight. Do not combine prescription treatments or change how you use them without speaking to the prescriber.
Can tretinoin be used on dark skin?
A randomised trial studied tretinoin for post-inflammatory marks in Black patients, and other trials studied melasma in Black patients. Those findings do not settle how every skin tone will respond. Irritation may worsen pigmentation, so anyone with skin of colour should discuss the risk and a plan for persistent irritation with their prescriber.
How we wrote this
We checked PubMed abstracts, UK medicine information, NHS advice, PCDS guidance and dermatology references. The trials are small or older and cover specific formulations and diagnoses. They cannot identify a reader’s mark or predict their response. This article provides general information and does not replace an individual assessment. Last reviewed 19 October 2026. Corrections: hello@retinoidlab.co.uk

